Compare CURI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURI | CRBU |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | 45 | N/A |
| Industry | Movies/Entertainment | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.6M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | CURI | CRBU |
|---|---|---|
| Price | $3.34 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.83 | ★ $10.75 |
| AVG Volume (30 Days) | 376.4K | ★ 1.2M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 10.00% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.52 | N/A |
| Revenue Next Year | $16.90 | $10.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $0.66 |
| 52 Week High | $7.15 | $3.53 |
| Indicator | CURI | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 53.25 |
| Support Level | $3.07 | $1.70 |
| Resistance Level | $4.96 | $2.11 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 40.96 | 37.72 |
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.